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Background: Epidemiological studies of the association between nonsteroidal anti-inflammatory drug (NSAID)
intake and the risk of prostate cancer still remain controversial. Therefore, we conducted a meta-analysis to evaluate
the potential association between NSAID intake and prostate cancer risk.
Methods: Eligible studies were retrieved by both computerized searches and reviews of references. Subgroup
analyses on country and design of study were also performed. Random or fixed-effect models were used to pool
estimates of odds ratios (ORs) with 95% confidence intervals (CIs).
Results: We observed that the intake of aspirin was associated with a marginally decreased risk of prostate cancer
(OR =0.95, 95% CI =0.93 to 0.98). A similar result was found between nonaspirin NSAIDs and prostate cancer risk
(OR =0.94, 95% CI =0.90 to 0.98). However, a positive relation between all-NSAID intake and prostate cancer risk was
observed (OR =1.18, 95% CI =1.15 to 1.22).
Conclusions: We observed a marginally inverse correlation between the intake of aspirin and prostate cancer risk.
On the contrary, a positive relationship between all-NSAID intake and prostate cancer was detected. Further
research needs to be conducted to better clarify potential biological mechanisms.
Keywords: Etiology, Meta-analysis, NSAIDs, Prostate cancerBackground
Prostate cancer is generally accepted as the most common
type of cancer among men and ranks as the second cause
of cancer-specific death in the whole world [1]. In the
USA, approximately 238,590 men were diagnosed with
prostate cancer, of which 12% were expected to die in
2013 [1]. Epidemiologic studies illustrated that both envir-
onmental and genetic alterations are well-established risk
factors of prostate cancer [2,3]. However, this could hardly
explain the different incidences of prostate cancer in
different countries [1,4]. Therefore, daily lifestyle could
play an important role in carcinogenesis.
Previous research demonstrated that nonsteroidal
anti-inflammatory drugs (NSAIDs) could reduce the risk
of several types of cancer, including colorectal cancer,
esophageal cancer, and breast cancer [5-7]. Laboratory* Correspondence: xielp@zjuem.zju.edu.cn
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unless otherwise stated.research has consistently illustrated that inflammation
plays an essential role in prostate carcinogenesis [8]. It is
generally accepted that cyclooxygenase enzymes, which
are the targets of most NSAIDs, are involved in prostate
carcinogenesis. A previous review, focusing on the poten-
tial relationship between NSAID intake and prostate
cancer risk, showed that NSAIDs could prevent prostate
cancer from developing into advanced disease, suggesting
that NSAIDs could have a potentially protective effect on
prostate cancer [9].
Nevertheless, epidemiological studies of the association
between NSAID intake and the risk of prostate cancer still
remained controversial. A previous meta-analysis in 2010
(including articles published before 2008) indicated that
aspirin and other types of NSAID had a marginally, but
not conclusively, protective effect on prostate cancer [10].
In addition, multicenter and large-sample studies were
performed in the last 5 years, which provided us with
more reliable statistics.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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both the strength and consistency of the potential
association between NSAID intake and prostate cancer




To obtain an overall view of NSAID intake and prostate
cancer risk, we performed a comprehensive and systematic
searching strategy. We searched for publications updated to
October 2013 using PubMed, the Web of Science, and
Cochrane Library. We selected the keyword search
‘(“Anti-Inflammatory Agents, Non-Steroidal” [Mesh] OR
“Aspirin” [Mesh]) AND “Prostatic Neoplasms” [Mesh]’ to
identify publications. Additional publications were assessed
either by cited references in the recruited articles or
reported meta-analyses on NSAID intake and prostate
cancer risk. Each retrieved publication was evaluated
for the following criteria: (1) case-control or cohort study
assessing the potential correlation between NSAIDs intake
and prostate cancer risk; (2) exact data in both case and
control groups should be identified; (3) articles published
before October 2013 written in English; (4) results includ-
ing odds ratios (ORs) or relative risk and 95% confidence
intervals (95% CIs), or supplying sufficient information to
calculate them. Studies with insufficient or overlapping
data were excluded. Figure 1 illustrates the process of
determining and selecting articles.
Data extraction
Data extracted from the articles included the name of the
first author, year of publication, study period, country, typeFigure 1 Article selection.of NSAID, design of study, information resource, and odds
ratio comparing the highest level of NSAID intake with
the lowest. Given that prostate cancer is a relatively rare
disease, the relative risk was considered to be the same as
the OR. Therefore, we chose OR as the result to assess the
potential relationship between NSAID intake and prostate
cancer risk. Investigators were divided into two groups,
and extracted data from all the potentially qualifying pub-
lications simultaneously, to avoid omissions or mistakes.
Discussions were conducted whenever necessary.
Statistical analysis
A fixed-effects model using the method of Mantel and
Haenszel [11] was selected to provide pooled estimation of
the correlation between NSAID intake and prostate cancer
risk when no heterogeneity was detected; otherwise, the
random-effect model of the method of DerSiomonian and
Laird [12] was selected for summarization.
We chose OR and 95% CI to evaluate the strength of
the relationship between NSAID intake (all NSAIDs,
aspirin, and nonaspirin NSAIDs, respectively) and prostate
cancer risk (prostate cancer and advanced prostate cancer,
respectively). Advanced prostate cancer was defined as
Gleason score ≥8, clinical stage ≥T2C, or prostate-specific
antigen ≥10 ng/ml. Stratified analyses were conducted by
country (USA or other countries) and study design (cohort
study or case-control).
We used the quantified Q test [12] and I2 test [13] to
assess the extent of heterogeneity across eligible studies.
Publication bias was evaluated by Egger’s [14] and Begg’s
[15] tests. The statistical significance level was set at 0.05.
Sensitivity analyses were also conducted to evaluate
the effect of each study on the overall estimate.
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version 11 (StataCorp, College Station, Texas, USA).
Results
Description of the meta-analysis
A total of 334 articles were found when the mentioned
keywords were used. After a closer examination, 309
articles were excluded based on titles and abstracts,
while 4 articles were recruited from the reference lists of
reviews and included articles [16-19]. Figure 1 illustrates
the detailed process of identifying and selecting articles.
Finally, we identified a total of 29 articles on NSAID
intake and prostate cancer risk that were published be-
tween 1989 and 2013 [16-44].
Among the included articles, 15 were cohort studies
[16-20,22,24,28-30,33,36,37,39,40], and 14 were case-
control ones [21,23,25-27,31,32,34,35,38,41-44]. Sixteen
studies were conducted in the USA [16-18,20,22,24,25,28,
30,31,37,39-43], while the remaining 13 were performed
in other countries [19,21,23,26,27,29,32-36,38,44]. Eleven
studies were associated with all-NSAID intake [19,20,26-28,
32-34,38,42,44], 24 with aspirin [16-18,21-33,36-41,43,44],
and 14 with nonaspirin NSAIDs [23,25-28,30,32,35,36,
38-41,44]. Eleven studies were concerned about advanced
prostate cancer [18,24,26-28,30,37-39,41,43]. Information
was collected from either databases or questionnaires.
Detailed characteristics of the eligible studies are listed
in Table 1.
Intake of aspirin and prostate cancer
Of the 24 studies concerned with aspirin intake, we
observed that the intake of aspirin was associated with a
marginally decreased risk of prostate cancer (OR =0.95,
95% CI =0.93 to 0.98) (Figure 2). A statistical heterogen-
eity was detected, therefore, random-effect analysis was
performed (I2 = 60.7%, P <0.001). The risk of advanced
prostate cancer was lower than that of prostate cancer
(OR =0.89, 95% CI =0.82 to 0.96). The fixed-effect ana-
lysis was conducted and no significant heterogeneity was
found (I2 = 4.5%, P =0.4).
Begg’s and Egger’s tests were performed to evaluate
publication bias among the included studies; no such
bias was found by either Begg’s or Egger’s test (P =0.503,
P =0.160, respectively).
For stratified analysis, the summarized OR estimates
indicated that the intake of aspirin was associated with a
decreased risk of prostate cancer in the USA (OR =0.937,
95% CI =0.900 to 0.975). However, no such associ-
ation was detected in other countries (OR =0.969,
95% CI =0.934 to 1.006). When subgroup analysis was
performed by study design, we observed a marginally pro-
tective effect of aspirin on prostate cancer in the cohort
group (OR =0.930, 95% CI =0.894 to 0.967). Neverthe-
less, no such effect was found in the case-control group(OR =0.976, 95% CI =0.940 to 1.013). Detailed data are
given in Table 2.All-NSAID intake and prostate cancer
A total of 11 studies were associated with all-NSAID
intake and prostate cancer. Compared with previous
meta-analyses, we observed a positive relationship be-
tween all-NSAID intake and prostate cancer risk, owing
to new research (OR =1.18, 95% CI =1.15 to 1.22). A
random-effect analysis was conducted, owing to signifi-
cantly statistical heterogeneity (I2 = 92.4%, P <0.001).
Similar results were found between all-NSAID intake
and advanced prostate cancer (OR =1.43, 95% CI =1.32
to 1.56, I2 = 92.8%, P <0.001). No publication bias was
detected when Begg’s and Egger’s tests were conducted
(P =0.312, P =0.190, respectively).
In the subgroup analysis, the pooled OR estimates
suggested that no direct relationship between all-
NSAID intake and prostate cancer risk was observed in
the USA (OR =0.922, 95% CI =0.836 to 1.016). Notably,
we detected a positive correlation between all-NSAID in-
take and prostate cancer risk (OR =1.212, 95% CI =1.174
to 1.251). When stratified analysis was conducted by study
design, we did not observe a protective effect on prostate
cancer in the cohort group (OR =1.022, 95% CI =0.938 to
1.113). However, in case-control groups, all-NSAID intake
could be a potential risk factor in prostate carcinogenesis
(OR =1.205, 95% CI =1.167 to 1.245). Detailed data are
illustrated in Table 2.Nonaspirin NSAID intake and prostate cancer
Among the 14 articles related to nonaspirin NSAIDs and
prostate cancer risk, we observed a marginally inverse
relation (OR =0.94, 95% CI =0.90 to 0.98) (Figure 3). A
significantly statistical heterogeneity was observed, thus
random-effect analysis was performed (I2 = 55.9%, P <0.01).
Nevertheless, an opposite relation was detected between
nonaspirin NSAID intake and advanced prostate cancer
(OR =1.25, 95% CI =1.13 to 1.38, I2 = 65.8%, P <0.01).
Begg’s and Egger’s tests were conducted to assess for
publication bias among the included articles; no such bias
was detected by either Begg’s or Egger’s test (P =0.956,
P =0.500, respectively).
In the stratified analysis, the summarized OR estimates
showed that nonaspirin NSAIDs were associated with a
decreased risk of prostate cancer in other countries
except the USA (OR =0.915, 95% CI =0.869 to 0.964).
However, we failed to find a similar relation in the USA
(OR =1.009, 95% CI =0.927 to 1.099). When stratified
analysis was performed on study design, we observed a
marginally protective effect on prostate cancer in the
case-control group (OR =0.922, 95% CI =0.876 to 0.971).
Nevertheless, no such result was detected in the cohort
Table 1 Characteristics of the included studies on nonsteroidal anti-inflammatory drugs intake and prostate cancer
First author Published year Study design Country Drugs Study period Information resource
Paganini-Hill [16] 1989 Cohort USA Aspirin 1981 to 1988 Questionnaire
Schreinemachers [22] 1994 Cohort USA Aspirin 1971 to 1987 Questionnaire
Neugut [31] 1998 Case-control USA Aspirin 1984 to 1986 Questionnaire
Norrish [38] 1998 Case-control New Zealand Aspirin, NA-NSAIDs, NSAIDs 1996 Questionnaire
Nelson [25] 2000 Case-control USA Aspirin, NA-NSAIDs 1992 to 1995 Questionnaire
Langman [34] 2000 Case-control UK NSAIDs 1993 to 1995 Database
Leitzmann [18] 2002 Cohort USA Aspirin 1986 to 1998 Questionnaire
Roberts [20] 2002 Cohort USA NSAIDs 1990 to 1996 Questionnaire
Habel [24] 2002 Cohort USA Aspirin 1964 to 1996 Questionnaire
Irani [35] 2002 Case-control France NA-NSAIDs 1999 to 2000 Questionnaire
Sorensen [19] 2003 Cohort Denmark NSAIDs 1989 to 1995 Database
Friis [29] 2003 Cohort Denmark Aspirin 1989 to 1997 Database
Perron [33] 2003 Cohort Canada Aspirin, NSAIDs 1993 to 1996 Database
Ratnasinghe [17] 2004 Cohort USA Aspirin 1976 to 1992 Questionnaire
García Rodríguez [36] 2004 Cohort UK Aspirin, NA-NSAIDs 1995 to 2001 Database
Jacobs [28] 2005 Cohort USA Aspirin, NA-NSAIDs, NSAIDs 1992 to 2001 Questionnaire
Platz [40] 2005 Cohort USA Aspirin, NA-NSAIDs 1980 to 2004 Questionnaire
Bosetti [21] 2006 Case-control Italy Aspirin 1991 to 2002 Questionnaire
Dasgupta [23] 2006 Case-control Canada Aspirin, NA-NSAIDs 1999 to 2002 Database
Mahmud [26] 2006 Case-control Canada Aspirin, NA-NSAIDs, NSAIDs 1999 to 2003 Questionnaire
Menezes [41] 2006 Case-control USA Aspirin, NA-NSAIDs 1982 to 1998 Questionnaire
Murad [32] 2010 Case-control UK Aspirin, NA-NSAIDs, NSAIDs 2001 to 2008 Database
Brasky [39] 2010 Cohort USA Aspirin, NA-NSAIDs 2000 to 2007 Questionnaire
Coogan [42] 2010 Case-control USA NSAIDs 1992 to 2008 Questionnaire
Salinas [43] 2010 Case-control USA Aspirin 2002 to 2005 Questionnaire
Dhillon [37] 2011 Cohort USA Aspirin 1988 to 2006 Questionnaire
Mahmud [44] 2011 Case-control Canada Aspirin, NA-NSAIDs, NSAIDs 1985 to 2000 Questionnaire
Shebl [30] 2012 Cohort USA Aspirin, NA-NSAIDs 1993 to 2009 Questionnaire
Veitonmaki [27] 2013 Case-control Finland Aspirin, NA-NSAIDs, NSAIDs 1995 to 2002 Database
NA-NSAIDs, nonaspirin nonsteroidal anti-inflammatory drugs; NSAIDs, total nonsteroidal anti-inflammatory drugs.
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data are illustrated in Table 2.
Sensitivity analysis
Simultaneously, sensitivity analyses were conducted to
evaluate the effect of each study on the overall estimate
by sequentially excluding each study in turn. In our
meta-analysis, we found that probably no study could
affect the summary of risk estimate (data not shown).
Discussion
Nonsteroidal anti-inflammatory drugs are one of the
most commonly used medicine types in the whole world.
Studies showed that daily nonsteroidal anti-inflammatory
drug intake could be a non-invasive, economical, and
valuable method of preventing cancer. Previous researchillustrated that inflammation was involved in the process
of prostate carcinogenesis [45]. Evidence demonstrated
that cyclooxygenase enzymes, the targets of most NSAIDs,
played a critical role in the development of prostate cancer
[8]. Further studies verified that NSAIDs could inhibit the
development and progression of prostate cancer, which
meant that NSAIDs might be effective in the prevention
of prostate cancer [9]. Nevertheless, conflicting results
were obtained by different research centers. Therefore, we
performed a meta-analysis to evaluate both the strength
and consistency of the potential association between
NSAID intake and prostate cancer risk.
We observed that the intake of aspirin was associated
with a marginally decreased risk of prostate cancer
(OR =0.95, 95% CI =0.93 to 0.98). The risk of advanced
prostate cancer was less than that of prostate cancer
Figure 2 Forest plots depicting the risk estimates from included studies on the association between the intake of aspirin and prostate
cancer risk. CI, confidence interval; OR, odds ratio.
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the intake of aspirin showed a marginally inverse cor-
relation with prostate cancer risk. The results of the 24
studies included in our analysis were heterogeneous,
probably resulting from differences in country and study
design. To further illustrate the relationship between the
intake of aspirin and prostate cancer risk, subgroup
analyses were conducted. The summarized OR estimates
illustrated that the intake of aspirin was associated with a
decreased risk of prostate cancer while separately analyzedTable 2 Stratified pooled odds ratios and 95% confidence int















Case-control studies 9by country and design of study. In the stratified analysis
by country, we found that an inversed correlation between
the intake of aspirin and prostate cancer risk in the USA
(OR =0.937, 95% CI =0.900 to 0.975). Conversely, no such
association was observed in other countries (OR =0.969,
95% CI =0.934 to 1.006). Additionally, we found that none
of the studies analyzing the association between the intake
of aspirin and prostate cancer risk was conducted in Asian
countries, probably because of different daily habits in
those countries; this aspect requires further research.ervals of NSAIDs intake and prostate cancer
tio (95% confidence interval) Heterogeneity
P I2 (%)
0.937 (0.900, 0.975) 0.012 52.0
0.969 (0.934, 1.006) 0.000 70.0
0.930 (0.894, 0.967) 0.025 48.6
0.976 (0.940, 1.013) 0.000 69.0
0.922 (0.836, 1.016) 0.011 77.7
1.212 (1.174, 1.251) 0.000 92.7
1.022 (0.938, 1.113) 0.000 90.2
1.205 (1.167, 1.245) 0.000 93.3
1.009 (0.927, 1.099) 0.807 0.0
0.915 (0.869, 0.964) 0.001 70.3
0.992 (0.909, 1.083) 0.629 0.0
0.922 (0.876, 0.971) 0.002 67.9
Figure 3 Forest plots depicting the risk estimates from included studies on the association between nonaspirin NSAID intake and
prostate cancer risk. CI, confidence interval; OR, odds ratio.
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intake and prostate cancer risk. We found a positive
relation between all-NSAID intake and prostate cancer
risk, owing to more recent research, compared with pre-
vious meta-analyses (OR =1.18, 95% CI =1.15 to 1.22).
Similar results were found between all-NSAID intake
and advanced prostate cancer (OR =1.43, 95% CI =1.32
to 1.56). To explain the phenomenon, we took a deeper
look at the included studies. One study conducted in
Finland illustrated a significantly elevated prostate cancer
risk of total and advanced prostate cancer among all-
NSAID users [27]. The association was not dose-dependent
in the study, indicating that it could result from systematic
differences between users of prescription NSAIDs and users
of non-prescription NSAIDs. Furthermore, people who take
prescribed NSAIDs are possibly frequent users of other
health services, such as cancer screening, including testing
for prostate-specific antigen. This could bring about a posi-
tive detection bias.
Meanwhile, among the 14 articles associated with non-
aspirin NSAIDs and prostate cancer risk, we observed a
marginally inverse correlation between them (OR =0.94,
95% CI =0.90 to 0.98). Nevertheless, an opposite correl-
ation was detected between nonaspirin NSAIDs intake
and advanced prostate cancer (OR =1.25, 95% CI =1.13
to 1.38).
Our study could have limitations in several ways
Firstly, although no publication bias was detected in our
analysis, using both Begg’s and Egger’s tests, the strategy
of selection of published studies in English only and the
exclusion of studies without sufficient information couldbring about possible publication bias, which remains an
alternative explanation of our results. Furthermore, our
search was restricted to published articles, which could
also cause potential bias to affect our findings.
Secondly, both case-control and cohort studies with
different populations, drug intakes, and outcomes were
included in our analysis. Considering the existing hetero-
geneity, it could be inappropriate to choose a single global
effect estimate to pool the data, and the summarized esti-
mates in our study should be treated with caution [46].
Therefore, we performed stratified analyses to explain the
possible sources of heterogeneity [47]. Additionally, some
studies were case-control ones; these could lead to selec-
tion and recall bias.
Thirdly, there are several types of NSAID, which could
have different effects on prostate cancer. However, most
studies recruited in our study merely provided general
data on NSAID intake rather than detailed information
on specific dose and duration of use, which might bring
about inaccurate estimates.
Conclusions
We conducted a detailed meta-analysis for summarized
OR estimates from researches focused on the association
between NSAIDs intake and prostate cancer risk. Al-
though we could not deny possible confounding fac-
tors, the results indicated a marginally inverse correlation
between the intake of aspirin and prostate cancer risk. On
the contrary, a positive relation between all-NSAID intake
and prostate cancer was observed. Further research needs
to be conducted to better clarify potential biological
mechanisms.
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